静脉注射丙种球蛋白无反应型川崎病的诊治进展

摘要
图/表
参考文献(31)
相关文章 (10)
点击分布统计
下载分布统计

	［1］Durongpisitkul K, Soongswang J, Laohaprasitiporn D, Nana A, Prachuabmoh C, Kangkagate C. Immunoglobulin failure and retreatment in Kawasaki disease［J］. Pediatr Cardiol, 2003, 24(2):145-148.
	［2］Sittiwangkul R, Pongprot Y, Silvilairat S, Phornphutkul C. Management and outcome of intravenous gammaglobulin-resistant Kawasaki disease［J］. Singapore Med J, 2006 , 47(9):780-784.
	［3］Brogan PA, Bose A, Burgner D, Shingadia D, Tulloh R, Michie C, et al. Kawasaki disease: an evidence based approach to diagnosis, treatment, and proposals for future research［J］. Arch Dis Child, 2002, 86(4): 286-290.
	［4］Minami T, Suzuki H, Takeuchi T, Uemura S, Sugatani J, Yoshikawa N. A polymorphism in plasma platelet-activating factor acetylhydrolase is involved in resistance to immunoglobulin treatment in Kawasaki disease［J］. J Pediatr, 2005, 147(1): 78-83.
	［5］杨军, 李成荣, 李永柏, 李若馨, 孙来保, 黄惠君, 等. 肿瘤坏死因子α和白细胞介素10基因启动子区多态性与川崎病的相关性研究［J］. 中华儿科杂志, 2003, 41(8): 598-602.
	［6］Ashouri N, Takahashi M, Dorey F, Mason W. Risk factors for nonresponse to therapy in Kawasaki disease ［J］. J Pediatr, 2008, 153(3): 365-368.
	［7］Tremoulet AH, Best BM, Song S, Wang S, Corinaldesi E, Eichenfield JR, et al. Resistance to intravenous immunoglobulin in children with Kawasaki disease［J］. J Pediatr, 2008, 153(1):117-121.
	［8］Uehara R, Belay ED, Maddox RA, Holman RC, Nakamura Y, Yashiro M,et al. Analysis of potential risk factors associated with nonresponse to initial intravenous immunoglobulin treatment among Kawasaki disease patients in Japan［J］. Pediatr Infect Dis J, 2008, 27(2):155-160.
	［9］杜忠东, 张永兰, 赵地, 杜军保, 鲁珊, 衣京梅, 等. 静脉丙种球蛋白无反应性川崎病的治疗及危险因素分析［J］. 中国实用儿科杂志, 2006, 21(10):738-741.
	［10］Okada K, Hara J, Maki I, Miki K, Matsuzaki K, Matsuoka T, et al. Pulse methylprednisolone with gammaglobulin as an initial treatment for acute Kawasaki disease［J］. Eur J Pediatr, 2009, 168(2):181-185.
	［11］Cha S, Yoon M, Ahn Y, Han M, Yoon KL. Risk factors for failure of initial intravenous immunoglobulin treatment in Kawasaki disease［J］. J Korean Med Sci, 2008, 23(4):718-722.
	［12］野中善男. かソフロブミソ不仄例［J］. 小兒科, 2000, 41(5): 547-553.
	［13］Sano T, Kurotobi S, Matsuzaki K, Yamamoto T, Maki I, Miki K, et al. Prediction of non-responsiveness to standard high-dose gammaglobulin therapy in patients with acute Kawasaki disease before starting initial treatment［J］. Eur J Pediatr, 2007, 166(2):131-137.
	［14］Kuo HC, Yang KD, Liang CD, Bong CN, Yu HR, Wang L, et al. The relationship of eosinophilia to intravenous immunoglobulin treatment failure in Kawasaki disease［J］. Pediatr Allergy Immunol, 2007, 18(4):354-359.
	［15］Terai M, Honda T, Yasukawa K, Higashi K, Hamada H, Kohno Y. Prognostic impact of vascular leakage in acute Kawasaki disease［J］. Circulation, 2003, 108(3): 325-330.
	［16］Freeman AF, Shulman ST. Refractory Kawasaki disease［J］. Pediatr Infect Dis J, 2004, 23(5): 463-464.
	［17］Uehara R, Yashiro M, Oki I, Nakamura Y, Yanagawa H. Re-treatment regimens for acute stage of Kawasaki disease patients who failed to respond to initial intravenous immunoglobulin therapy: analysis from the 17th nationwide survey［J］. Pediatr Int, 2007, 49(4): 427-430.
	［18］薗部友良, 土屋惠司. 川崎病不全型の臨床的特徴とその診断法［J］. 小児科診療, 2006, 69(7):981-986.
	［19］Miura M, Ohki H, Tsuchihashi T, Yamagishi H, Katada Y, Yamada K, et al. Coronary risk factors in Kawasaki disease treated with additional gammaglobulin［J］. Arch Dis Child, 2004, 89(8):776-780.
	［20］Dale RC, Saleem MA, Daw S, Dillon MJ. Treatment of severe complicated Kawasaki disease with oral prednisolone and aspirin［J］. J Pediatr, 2000, 137(5):723-726.
	［21］Takeshita S, Kawamura Y, Nakatani K, Tsujimoto H, Tokutomi T. Standard-dose and short-term corticosteroid therapy in immunoglobulinresistant Kawasaki disease［J］. Clin Pediatr (Phila), 2005, 44(5):423-426.
	［22］Miura M, Kohno K, Ohki H, Yoshiba S, Sugaya A, Satoh M. Effects of methylprednisolone pulse on cytokine levels in Kawasaki disease patients unresponsive to intravenous immunoglobulin［J］. Eur J Pediatr, 2008, 167(10): 1119-1123.
	［23］Miura M, Matsuoka M, Kohno K, Ohki H, Yoshiba S. Methylprednisolone pulse therapy in Kawasaki disease［J］. Nippon Rinsho, 2008, 66(2):338-342.
	［24］Furukawa T, Kishiro M, Akimoto K, Nagata S, Shimizu T, Yamashiro Y. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease［J］. Arch Dis Child, 2008, 93(2):142-146.
	［25］Imagawa T, Mori M, Miyamae T, Ito S, Nakamura T, Yasui K, et al. Plasma exchange for refractory Kawasaki disease［J］. Eur J Pediatr, 2004, 163(4-5):263-264.
	［26］Zaitsu M, Hamasaki Y, Tashiro K, Matsuo M, Ichimaru T, Fujita I, et al. Ulinastatin, an elastase inhibitor, inhibits the increased mRNA expression of prostaglandin H2 synthase-type 2 in Kawasaki disease［J］. J Infect Dis, 2000, 181(3): 1101-1109.
	［27］Weiss JE, Eberhard BA, Chowdhury D, Gottlieb BS. Infliximab as a novel therapy for refractory Kawasaki disease［J］. J Rheumatol, 2004, 31(4):808-810.
	［28］Stenbog EV, Windelborg B, Horlyck A, Herlin T. The effect of TNFalpha blockade in complicated, refractory Kawasaki disease［J］. Scand J Rheumatol, 2006, 35(4): 318-321.
	［29］Ahn SY, Kim DS. Treatment of intravenous immunoglobulin-resistant Kawasaki disease with methotrexate［J］. Scand J Rheumatol, 2005, 34(2):136-139.
	［30］Raman V, Kim J, Sharkey A, Chatila T. Response of refractory Kawasaki disease to pulse steroid and cyclosporin A therapy［J］. Pediatr Infect Dis J, 2001, 20(6): 635-637.
	［31］Lucron H, Bosser G, Lethor JP, Sommelet D, Feillet F, Burger G, et al. Kawasaki disease in newborns and infants: refractory forms to immunoglobulin therapy［J］.Arch Mal Coeur Vaiss, 2004, 97(5): 522-528.